Analysts expect a negative impact on ResMed Inc. (RMD) after privately held pharmaceutical company and rival Apnimed, Inc.

Growth is driven by rising lifestyle-related disorders like diabetes and obesity, spurring obstructive sleep apnea. The home ...

The stock's rise snapped a four-day losing streak.

A month has gone by since the last earnings report for ResMed (RMD). Shares have added about 4% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to ...

Shares of ResMed Inc. RMD shed 1.08% to $242.84 Friday, on what proved to be an all-around rough trading session for the ...

The company saw its revenue, operating income, and net income rise steadily over the years (see table below). Free cash flow ...

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has ...

ResMed is taking a “smart devices” and Big Data approach to further entrench itself as one of the two leading players in the global obstructive sleep apnea, or OSA, market. With cloud ...

April 23 (Reuters) - Resmed (RMD.N), opens new tab beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep ...